| Literature DB >> 29110709 |
Do Hung Son1, Nguyen Thuy-Nhien1, Lorenz von Seidlein2,3, Truong Le Phuc-Nhi1, Ngo Thi Phu1, Nguyen Thi Kim Tuyen1, Nguyen Huyen Tran1, Nguyen Van Dung4, Bui Van Quan4, Nicholas P J Day2,3, Arjen M Dondorp2,3, Nicholas J White2,3, Guy E Thwaites1,3, Tran Tinh Hien5,6.
Abstract
BACKGROUND: Prophylaxis for high-risk populations, such as forest workers, could be one component for malaria elimination in the Greater Mekong Sub-region. A study was conducted to assess the malaria incidence in forest rangers and the feasibility of malaria prophylaxis for rangers sleeping in forest camps.Entities:
Keywords: An. barbirostris; An. dirus; An. maculatus; Anti-malarial resistance; DHA; Forest; Kelch K13-C580Y; Piperaquine; Plasmepsin; Plasmodium falciparum; Plasmodium vivax; Prophylaxis
Mesh:
Substances:
Year: 2017 PMID: 29110709 PMCID: PMC5674731 DOI: 10.1186/s12936-017-2091-6
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Map of National Park Bu Gia, Binh Phuoc Province, Vietnam, with forest ranger stations and campsites
Fig. 2Assembly and flow of study participants
Time spans (median and interquartile range)
| ACT | IQR | Placebo | IQR | All | IQR | |
|---|---|---|---|---|---|---|
| Duration of last forest stay before enrolment (days) | 8 | 4–13 | 8 | 5–14 | 8 | 5–12 |
| Days since last forest stay | 7 | 7–28 | 7 | 7–28 | 7 | 7–14 |
| Days between start drug administration* and return to forest | 19 | 19–28 | 19 | 18–20 | 19 | 18–19 |
| Days in forest | 8 | 5–12 | 10 | 3–10 | 9.5 | 5–10 |
| Days between return to forest and last screening | 28 | 23–34 | 28 | 23–34 | 28 | 23–34 |
| Duration of study participation (days) | 47 | 42–54 | 47 | 42–54 | 47 | 42–54 |
* 3 days DHA/piperaquine and 14 days PQ
Demographic, clinical, and parasitological characteristics of 150 study participants
| ACT | %, 95% CI | Placebo | %, 95% CI | Total | P value | |
|---|---|---|---|---|---|---|
| n | 75 | 50% | 75 | 50% | 150 | |
| Baseline | ||||||
| Male | 75 | 100% | 75 | 100% | 150 | 1 |
| Age (years; mean; 95% CI) | 30.6 | 28.4–32.9 | 33.1 | 30.6–35.7 | 32.9 | 0.9 |
| Weight (kg, mean; 95% CI) | 58.3 | 56.5–60.2 | 58.4 | 56.5–60.4 | 58.4 | 0.9 |
| Temperature (celsius; mean; 95% CI) | 36.2 | 36.1–36.3 | 36.2 | 36.1–36.3 | 36.2 | 0.9 |
| Fever (temp > 37.4) | 0 | 0% | 1 | 1% | 1 | 0.3 |
| Employment: farmer | 73 | 97% | 75 | 100% | 148 | 0.4 |
| uPCR positive | 18 | 24% | 12 | 16% | 30 | 0.2 |
| | 8 | 11% | 4 | 5% | 12 | 0.4 |
| | 7 | 9% | 2 | 3% | 9 | 0.2 |
| | 1 | 1% | 1 | 1% | 2 | 1 |
| | 2 | 3% | 5 | 7% | 7 | 0.4 |
| RDT positive | 2 | 3% | 1 | 1% | 3 | 0.6 |
| Microscopy positive | 3 | 4% | 1 | 1% | 4 | 0.3 |
| Hb (mg/dl; mean; 95% CI) | 14.6 | 14.2–14.9 | 14.7 | 14.3–15.0 | 14.6 | 0.7 |
| Pre-forest entry | ||||||
| Fever (temp > 37.4) | 0 | 0% | 0 | 0% | 0 | 1 |
| uPCR pos | 1 | 1% | 4 | 5% | 5 | 0.4 |
| Pf | 1 | 1% | 2 | 3% | 3 | 1 |
| Pv | 0 | 0% | 0 | 0% | 0 | na |
| Pspp | 0 | 0% | 2 | 3% | 2 | 0.5 |
| RDT positive | 0 | 0% | 0 | 0% | 0 | na |
| Microscopy positive | 0 | 0% | 0 | 0% | 0 | na |
Key data of 3 study participants infected on enrolment and 2 participants who acquired Plasmodium infections during the study period
| Participant | #107 | #124 | #006 |
|---|---|---|---|
| Baseline | |||
| Date 1 | 21/7/16 | 24/8/16 | 20/5/16 |
| Species |
|
| Not infected |
| K13 | C580Y | Not tested | |
| ExoE415G | E415G | ||
| P14 CNV | Single copy | ||
| Pfmdr1 CNV | Single copy | ||
| Parasites/ml | 22,225 | 1505 | |
| Treatment 1 | ACT + 14 days primaquine (15 mg/day) | ||
| Pre-forest entry | |||
| Date 2 | 7/8/16 | 9/10/16 | 6/6/16 |
| Species |
| Not infected |
|
| K13 | C580Y | Wild type | |
| ExoE415G | E415G | Insufficient DNA sample for testing | |
| P14 CNV | Multicopies | ||
| Pfmdr1 CNV | Single copy | Single copy | |
| Parasites/ml | 6412 | 663 | |
| Treatment 2 | ACT | ACT | Placebo |
| Forest days | 10 | 5 | 20 |
| Camp | Not known | Campsitea | Camp 8 |
| 15 days after return from forest | |||
| Date 3 | 6/9/16 | 4/11/16 | 12/7/16 |
| Species | Not infected |
|
|
| K13 | C580Y | C580Y | |
| ExoE415G | E415G | E415G | |
| P14 CNV | Multicopies | Multicopies | |
| Pfmdr1 CNV | Single copy | Single copy | |
| Parasites/ml | 5142 | 111,500 | |
aCamp: “campsite” refers to an overnight campsite while the rangers are moving through the forest
Exposure and parasitaemia detected after returning from forest at the end of the study
| ACT | %, 95% CI (n = 75) | Placebo | %, 95% CI (n = 75) | Total | P value | |
|---|---|---|---|---|---|---|
| Did you use a bed net? | ||||||
| Every night | 49 | 65% | 50 | 67% | 99 | 1.0 |
| Some nights | 16 | 21% | 11 | 15% | 27 | 0.4 |
| No bed net use | 10 | 13% | 14 | 19% | 24 | 0.5 |
| Did you use insect-repellent coil? | 18 | 24% | 8 | 11% | 26 | 0.05 |
| How many people did you meet while in forest (mean; 95% CI) | 5.0 | 4.5–5.5 | 4.8 | 4.6–5.1 | 4.9 | 0.7 |
| uPCR pos— | 1 | 1% | 1 | 1% | 2 | 1 |
| RDT positive | 0 | 0% | 0 | 0% | 0 | na |
| Microscopy positive | 0 | 0% | 1 | 1% | 1 | 1 |